ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

Size: px
Start display at page:

Download "ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE"

Transcription

1 CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

2 AT KANTAR HEALTH, ONCOLOGY IS WHAT WE DO! WE ARE GLOBAL EXPERTS IN BRINGING TOGETHER SCIENTIFIC AND COMMERCIAL RESEARCH TO DELIVER THE UNIQUE ONCOLOGY INSIGHTS AND COMMERCIAL STRATEGIES YOU NEED TO ACHIEVE BRAND SUCCESS. Kantar Health oncology solutions offers: years of deep oncology expertise and thought leadership. + + More than 100 dedicated oncology experts PhDs, Pharm D, and MDs ex-pharma market access and commercial brand experts market researchers, consultants, data scientists and creatives. + + Offices across the globe, on 5 continents and in 40 countries custom oncology engagements in the last year alone covering more than 50 solid tumors and hematologic malignancies. + + A wide breadth of work with more than 150 oncology clients, including Big Pharma, BioTech, research and non-profit companies. + + An extensive published research record, with more than 120 oncologyrelated publications in conferences and medical journals. + + Impactful global qualitative and quantitative research, with experts who have native language skills. WORLD CLASS EXPERTISE, EXPERIENCE AND DATA ASSETS Kantar Health oncology solutions is the one place where Expertise, Experience and proprietary data resources intersect to deliver valuable insights to help you navigate the complex and everevolving oncology landscape. Simply, our experts convert complex nuances within the oncology landscape into simple, actionable business solutions. We re recognized globally as leaders in oncology consulting and market research by the world s most trusted oncology companies. We ll provide you with the insights, resources, and data needed to determine commercial potential and optimal market strategy, ultimately increasing the probability of commercial success. Kantar Health has the unique ability to collect, analyze, and interpret customized datasets, including linked data sources, enabling us to make strategic recommendations for winning commercial decisions. + + Proprietary data resources not found anywhere else in the industry. Our engagements span the product lifecycle from early-stage/discovery to post-marketing/surveillance. Only Kantar Health oncology solutions combines experts, data and insights with the analytics and tools necessary for product growth. 2 3

3 FOCUSED: THREE AREAS OF DISCIPLINE Our oncology experts focus on three areas that address key elements across the product lifecycle: Portfolio Planning, Clinical Development Strategy and Commercial Planning and Insights are the disciplines that form the structural foundation of Kantar Health Oncology. PORTFOLIO PLANNING CLINICAL DEVELOPMENT STRATEGY COMMERCIAL PLANNING & INSIGHTS Portfolio Prioritization Clinical Trial Optimization Market Landscape Assessment Competitive Intelligence Market Sizing & Epidemiology Patient Journey/Buying Process Clinical Evaluations Tumor Landscape Assessments Segmentation Competitive Event Assessment Competitive Positioning Analysis Brand Positioning Epidemiology/Patient Targeting Target Product Profile Assessment Key Influencer/Stakeholder Mapping Market Access & Pricing KOL Assessment Brand Equity Evaluation: PINNAKLE Brand & Franchise Commercial Strategy Qualitative & Quantitative Market Research Pre-clinical 4 Pre-launch Launch Post Launch Brand Optimization 5

4 DEDICATED: SIX EXPERT ONCOLOGY TEAMS Oncology is what we do, and Kantar Health s oncology solutions are supported by six expert oncology teams that provide specialized knowledge and proficiency related to specific areas of the oncology market. Our clients receive exclusive access to oncology stakeholders through Kantar s Lightspeed panel of payors and providers CLINICAL AND SCIENTIFIC CONSULTING FORECASTING AND ANALYTICS EPIDEMIOLOGY QUALITATIVE AND QUANTITATIVE RESEARCH & INSIGHTS ANALYTICS MARKET ACCESS & COMMERCIAL STRATEGY REAL WORLD EVIDENCE While each team has their own expertise, Kantar Health brings together multiple teams to provide creative, innovative solutions to your specific business needs no request is too big or small. We work with a blended team of epidemiology, oncology consulting, and forecasting experts to determine how new data and current agents will shape your agent s entry into the market. We leverage the knowledge of oncology consulting, health outcomes, market access, and marketing insights to build patient, physician, payer, and / or caregiver preference studies to better understand the picture of what patients and providers hope to achieve with new drug regimens. 6 7

5 HERITAGE: PROPRIETARY ONCOLOGY RESOURCES Kantar Health oncology solutions provides clients with a heritage of proprietary data resources not found anywhere else in the industry! For more than 20 years we have supplied the industry with a wide variety of oncology resources that the world s top oncology companies depend on. 8 9

6 CANCERMPACT CANCERLANDSCAPE TM ONCOLOGY FORECAST ARCHITECT ONCOLOGY MARKET ACCESS Getting from A to Z begins with CancerMPact the premier global oncology intelligence resource. CancerMPact features four integrated modules designed to provide clients with comprehensive business insights for the dynamic oncology landscape. CancerMPact covers more than 37 different tumor types across the US, EU-5, Japan, China and 9 additional countries. 4 MODULES Patient Metrics this cancer epidemiology module leverages data from cancer registries and combine it with expert analysis to act as the starting point for understanding your target population together with detailed treatment data to size any given tumor type. The CancerLandscape platform is an innovative, dynamic, webbased solution with an easy to navigate, visually impactful and highly interactive dashboard that makes data easy to interpret. Offering fast navigation of large datasets to better understand oncology medicine opportunities and the competitive landscape, CancerLandscape assists users in evaluating business development and licensing opportunities, identifying novel targets for drug development, comparing company pipelines, and understanding the competitive landscapes in multiple tumor types. Oncology Forecast Architect offers the flexibility to meet the unique requirements of oncology product forecasting and the functionality to simplify the modeling process so that users may focus on assumptions. Our cancer patient flow forecast approach takes into account: the partitioning of patients into commercially relevant segments, including lines of therapy, exposure of prior therapies, biomarkers, and varying competitive sets; and underlying assumptions for treatment allocation and rates of progression through various therapies. Key challenges addressed include: + + Precise calculations of Patients on Therapy Kantar Health s U.S. OMA deeply examines complex treatment and care dynamics through a multi-stakeholder lens delivering key insights that inform your commercial and market access strategies. Our OMA team routinely evaluates stakeholder dynamics in the cancer market, including exploring the impact of healthcare reform on oncology care. Additionally, we assess the changing structure of the cancer care delivery system, focusing on the treatment and business challenges and opportunities faced by oncologists, patients and payers as a result of the coverage policy and reimbursement trends that influence prescribing and impact affordability. Our OMA report features 10 modules, including: Treatment Architecture this module leverages robust primary market research surveys of physicians to gain a detailed understanding the current clinical management of cancer patients by tumor type, site, disease stage, treatment modalities, and drug therapy use. + + Irregular dosing patterns +Treatment + discontinuations + + Linking lines of therapy + + Cancer Care Dynamics +Treatment + Dynamics Trends + + Tumor-Specific Cancer Treatment Dynamics Future Trends and Insights this module delivers expert insights on impending changes in the competitive landscape in each tumor market, including new product introductions and label expansions of market products. CancerNFluence : Oncology KOL Mapping this key opinion leader (KOL) mapping module, driven by our proprietary CancerNFluence offering, delivers profiles of leading physicians in the United States and Europe who influence treatment decisions across multiple cancer types. + + Re-Treatment + + Spanning treatment durations longer than one year + + Government Health Policy Trends + + Patient Influence and Affordability + + Payer Mix Simulations + + Immunotherapy in Oncology + + Distribution Channel Dynamics 10 11

7 FOR MORE INFORMATION Please contact us at or visit ABOUT KANTAR HEALTH Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership. Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit

Immunotherapy in Oncology

Immunotherapy in Oncology Emerging Markets Market Access & Health Outcomes Immunotherapy in Oncology Comparing and contrasting payer and oncologist perspectives on the impact of a wave of immunotherapies (especially PD-1/PD-L1)

More information

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets

EPIDEMIOLOGY. Accurate, in-depth information for understanding and assessing targeted markets EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns

More information

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast

More information

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA US Chronic Care has outperformed the market by a factor 2-3x and continues

More information

Sound Off DR. GOOGLE S ROLE IN PRE-DIAGNOSIS THROUGH TREATMENT. Ipsos SMX. June 2014

Sound Off DR. GOOGLE S ROLE IN PRE-DIAGNOSIS THROUGH TREATMENT. Ipsos SMX. June 2014 Sound Off DR. GOOGLE S ROLE IN PRE-DIAGNOSIS THROUGH TREATMENT June 2014 Ipsos SMX : Sound bits (of advice) and bites (of research) from Ipsos SMX Ipsos social media research division, dedicated to providing

More information

CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES QUALITATIVE RESEARCH THROUGH A BEHAVIORAL ECONOMIC LENS

CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES QUALITATIVE RESEARCH THROUGH A BEHAVIORAL ECONOMIC LENS CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES QUALITATIVE RESEARCH THROUGH A BEHAVIORAL ECONOMIC LENS JEANETTE HODGSON & SARAH SMITH DECEMBER 2017 QUALITATIVE RESEARCH THROUGH A BEHAVIORAL ECONOMIC

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit

Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit Big Data & Predictive Analytics Case Studies: Applying data science to human data 1.03.2018 Big-Data.AI Summit Dr. Arnim Jost, Commercial Director Technology Copyright 2017 IQVIA. All rights reserved.

More information

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan

More information

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013 Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU

More information

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU

More information

What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden

What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden Sunil Ramkali Account Director, W Communication Agency 11 th November 2014

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major

More information

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general

More information

REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Dupilumab in the nine major pharmaceutical markets

More information

Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer,

Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer, Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer, Workstation), Technology (AI, Gamete Donation, IVF, ICSI,

More information

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product

More information

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m

More information

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report

More information

Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic

Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic Alpha-fetoprotein (AFP) Testing Market: By Cancer Type (Liver Cancer, Testes Cancer, Ovarian Cancer, Biliary Tract Cancer, Stomach Cancer, Pancreatic Cancer, Others (Cirrhosis, and Hepatitis)) & Geography-Forecast

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

Novartis: tackling adherence. ESPACOMP, September, 2010

Novartis: tackling adherence. ESPACOMP, September, 2010 Novartis: tackling adherence ESPACOMP, September, 2010 Novartis is a world-leading healthcare company Leading market position One of 20 largest companies by market capitalization Among most respected companies

More information

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India

More information

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022

LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC279DFR PUBLICATION DATE OCTOBER 2013 LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND Executive Summary Table below presents the key metrics of Lupuzor for Systemic Lupus Erythematosus (SLE)

More information

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco Strategic Plan 2013 2017 Executive Summary Society for Research on Nicotine and Tobacco Prepared By: Corona Insights Corona Insights, 2012 CoronaInsights.com CONTENTS Introduction... 1 Background... 1

More information

Radiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions

Radiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment

More information

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major

More information

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 Executive Summary Diovan (valsartan): Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Market Sales US - Diovan 5EU - Diovan Japan - Diovan

More information

NAVIFY Tumor Board NAVIFY

NAVIFY Tumor Board NAVIFY NAVIFY Tumor Board Make the most informed personalized treatment decisions possible by leveraging innovative technologies and the latest scientific and clinical data WHAT S INSIDE Key Takeaways NAVIFY

More information

Cyclokat (Dry Eye Syndrome)

Cyclokat (Dry Eye Syndrome) Cyclokat (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC191DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Cyclokat in the major pharmaceuticals

More information

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif

More information

Asia-Pacific Electrophysiology Market Outlook to 2020

Asia-Pacific Electrophysiology Market Outlook to 2020 Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...

More information

Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA

Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence March 27 2018 IIeX Health, Philadelphia, PA Overview Current Landscape Data Sources to generate Real

More information

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted

More information

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India

More information

NCCN TRENDS DEMOGRAPHICS. Results: January 2013 NON-SMALL CELL LUNG CANCER. Distribution of Respondent Types (n = 1,055) Page 1

NCCN TRENDS DEMOGRAPHICS. Results: January 2013 NON-SMALL CELL LUNG CANCER. Distribution of Respondent Types (n = 1,055) Page 1 NCCN TRENDS Results: January 2013 NCCN Trends is an analytics tool from the National Comprehensive Cancer Network (NCCN ) that surveys how clinicians across the U.S. and around the globe are delivering

More information

OAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING. September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV. For the Life Sciences Industry

OAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING. September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV. For the Life Sciences Industry OAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING For the Life Sciences Industry September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV Register at DecisionResourcesGroup.com/Events DEAR COLLEAGUE, Cancer affects

More information

Imaging Systems. Gene Saragnese EVP and GM Imaging Systems

Imaging Systems. Gene Saragnese EVP and GM Imaging Systems Imaging Systems Gene Saragnese EVP and GM Imaging Systems 1 Imaging Systems Strategy Drive Customer & Patient Experience Quality, reliability and service delivery Ease of use, speed, comfort, dose Deliver

More information

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) Executive Summary Table below provides a summary of the key metrics for Cariprazine in the seven major pharmaceutical

More information

Value growth in Human Nutrition & Health

Value growth in Human Nutrition & Health Value growth in Human Nutrition & Health Rick Greubel President Human Nutrition & Health US Field Trip September 4, 2014 Safe harbor statement This presentation may contain forward-looking statements with

More information

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is

More information

Integrating Project Management Standards within Business Technology Management (BTM)

Integrating Project Management Standards within Business Technology Management (BTM) Integrating Project Management Standards within Business Technology Management (BTM) gagnontech.org btm-forum.org stephane.gagnon@uqo.ca Prof. Université du Québec, Canada Objectives 1. Meet PM 2 community,

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase

More information

Boehringer Ingelheim Pharmaceuticals, Inc. & Univision. Making Diabetic Hispanics Healthier

Boehringer Ingelheim Pharmaceuticals, Inc. & Univision. Making Diabetic Hispanics Healthier Boehringer Ingelheim Pharmaceuticals, Inc. & Univision Making Diabetic Hispanics Healthier Agenda BIPI and the Hispanic segment Organizing and Executing to Win The Proof is in the Results Making Hispanics

More information

2018 Global Value-based Digital Dental Competitive Strategy Innovation and Leadership Award

2018 Global Value-based Digital Dental Competitive Strategy Innovation and Leadership Award 2018 Global Value-based Digital Dental Competitive Strategy Innovation and Leadership Award 2018 Contents Background and Company Performance Industry Challenges... 3 Strategy Innovation and Customer Impact...

More information

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:

More information

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - India Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in India 2012 We estimate the 2012 PsO drug

More information

eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Projected to grow at a CAGR of around 12%, eclinical solutions market is expected to witness significant

More information

Russia Cardiac Assist Devices Market Outlook to 2021

Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for

More information

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013

More information

Mexico Ostomy Drainage Bags Market Outlook to 2020

Mexico Ostomy Drainage Bags Market Outlook to 2020 Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...

More information

Bariatric Surgery Devices - North America Analysis and Market Forecasts

Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts BioPortfolio has been marketing business and market research

More information

2015 Investor Conference

2015 Investor Conference 2015 Investor Conference ACCELERATING PROFITABLE GROWTH Jill Schaaf President, Renal Care Teeramanas Tanaekakarapong, ESRD Patient, Bangkok, Thailand Becoming The Global Leader In Renal Care Our Global

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Opportunities and Challenges in the Development of Companion Diagnostics

Opportunities and Challenges in the Development of Companion Diagnostics Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine

More information

Transforming health through IT

Transforming health through IT @himsseurope HIMSS Europe 02 HIMSS Europe www.himss.eu The Leading Health IT Knowledge Organisation HIMSS Europe is a voice, advisor and thought leader of transformation through health IT. As an independent

More information

The Cigarette Market in Greece

The Cigarette Market in Greece The Cigarette Market in Greece Product Code: CG0145MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Greece report is a qualitative report providing extensive and

More information

Partnering for Growth

Partnering for Growth Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities

More information

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013 Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1150DFR / Published May 2013 Executive Summary Sofosbuvir and Sofosbuvir/Ledipasvir: Key Metrics in Nine

More information

Global In-Vitro-Fertilization Market: Trends and Opportunities ( )

Global In-Vitro-Fertilization Market: Trends and Opportunities ( ) Global In-Vitro-Fertilization Market: Trends and Opportunities (2015-2019) Global In-Vitro-Fertilization Market: Trends and Opportunities (2015-2019) BioPortfolio has been marketing business and market

More information

Member-centered cancer care In Georgia

Member-centered cancer care In Georgia Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One

More information

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018 36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

Watson Summit Prague 2017

Watson Summit Prague 2017 Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B

More information

GLOBAL NEUROSTIMULATION MARKET

GLOBAL NEUROSTIMULATION MARKET GLOBAL NEUROSTIMULATION MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d

More information

MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS

MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such

More information

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan Planning Case Study Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan On the vanguard of thought. Reimagining The futurecancer of healthcare Care requires nothing less. Planning

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for brexpiprazole in the Major Depressive Disorder

More information

DIGITAL DIABETES CARE MARKET READY TO TAKE OFF

DIGITAL DIABETES CARE MARKET READY TO TAKE OFF DIGITAL DIABETES CARE MARKET 2018-2022 READY TO TAKE OFF www.research2guidance.com A market study about diabetes apps, connected devices, and services 3 rd edition, 3 rd September 2018 Research2Guidance

More information

Corporate Presentation Fourth Quarter 2017

Corporate Presentation Fourth Quarter 2017 Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major

More information

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION

PROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition

More information

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017 LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting

More information

October 4 6, 2017 The W Hotel, Chicago, IL

October 4 6, 2017 The W Hotel, Chicago, IL October 4 6, 2017 The W Hotel, Chicago, IL Register for this and future events at https://drgconferences.com WELCOME Cancer affects us all. Some reading this have survived it. Many have watched loved ones

More information

View Report Details. Global Coronary Stent Market

View Report Details. Global Coronary Stent Market View Report Details Global Coronary Stent Market ------------------------------------------------- 2013 View Report Details Executive Summary Coronary heart diseases are nowadays becoming more and more

More information

Jefferies 2014 Global Healthcare Conference November Because people depend on us

Jefferies 2014 Global Healthcare Conference November Because people depend on us Jefferies 2014 Global Healthcare Conference November 2014 Because people depend on us Forward-looking statements This presentation and information communicated verbally to you may contain certain projections

More information

Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics

Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth and Forecast Analytics Dental Floss (Oral Hygiene) Market in South Korea - Outlook to 2020: Market Size, Growth

More information

Walgreens. Specialty Pharmacy Marketing Video

Walgreens. Specialty Pharmacy Marketing Video Walgreens Specialty Pharmacy Marketing Video AUDIO MIKE NAMETH: (ON-CAMERA) Hi, I m Michael Nameth. I have been an executive in the healthcare industry for more than 25 years. Recently, specialty pharmacy

More information

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan Planning Case Study Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan On the vanguard of thought. Reimagining The futurecancer of healthcare Care requires nothing less. Planning

More information

ph Meters Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

ph Meters Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research ph Meters Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " The ph meters market is expected to grow at a CAGR of 3% over the forecast period from 2016 to 2024." 31 October

More information

Purolite Life Sciences Brand Positioning Catalyst

Purolite Life Sciences Brand Positioning Catalyst Purolite Life Sciences Brand Positioning Catalyst Presenting Brand Therapy Perceptions Goals Admired Brands Brand Narrative Brand Legacy Brand Story Vision, Mission, Promise Primary Messaging Brand Therapy

More information

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013 Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic

More information

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Brintellix in the seven major pharmaceutical markets

More information

Introducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview

Introducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview Introducing NCCN Academy for Excellence & Leadership in Oncology April 2009 Program Overview In 2009, NCCN will launch the NCCN Academy for Excellence & Leadership in Oncology, a series of oncology certificate

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information